Ligand (LGND) announced that its partner Travere Therapeutics (TVTX) has received approval from the FDA for Filspari to reduce proteinuria in adult and pediatric patients aged eight years and older with focal segmental glomerulosclerosis without nephrotic syndrome.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: